An increasing number of innovative high-upfront cost and acute/chronic medicines are being approved with an evidence base which is emergent.

In these circumstances, Health Systems require a cautious approach to pricing to ensure value-for-money, but Manufacturers are under pressure to optimise pricing to maximise their returns.

Seeking to resolve this gap in needs through a negotiation on price alone is unsatisfactory and a shift towards Value-based (and more specifically Outcomes-based) Healthcare is required.

Whilst there are many initiatives to move in this direction, and many examples of outcomes-based contracting have already emerged, underlying governance and data landscape challenges remain unresolved, and Health Systems and Manufactures respectively continue to face uncertain financial exposures and deferred / uncertain returns.

The AIM4ALL Initiative has been established to address these pricing and reimbursement access challenges.

It is doing this under a ‘research’ umbrella, free of existing policy constraints and fear of unintended consequences, and by creating a trusted, multi-jurisdictional ‘Living Lab’ environment which is both governance and data ready for the testing of innovative approaches to pricing and reimbursement which protect Health Systems from risk and satisfy Manufacturer economic needs.

AIM4ALL has already aligned multiple stakeholders and developed a proof-of-concept solution, and plans are now being put in place to take this work into a limited scale ‘real world’ environment with a view to establishing a jurisdictional playbook for propagation across a wider network of Health Systems which recognise the need to deploy a ‘test of change’.